For the quarter ending 2026-03-31, INDV made $317M in revenue. $89M in net income. Net profit margin of 28.08%.
| Income Statement | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Net revenue | 317 | 357 | 314 | 302 |
| Cost of sales | 40 | 67 | 83 | 52 |
| Gross profit | 277 | 293 | 230 | 250 |
| Selling, general and administrative | 124 | 189 | 155 | 158 |
| Research and development | 16 | 21 | 33 | 21 |
| Acquired in-process research and development | - | 0* | 0 | - |
| Litigation settlement | - | -2 | 0 | 0 |
| Other operating (income) expense, net | - | 0* | -1 | - |
| Total operating expenses | 139 | - | 187 | - |
| Operating income | 137 | 81 | 43 | 72 |
| Interest (income) | 3 | 6 | 6 | 6 |
| Interest expense | 7 | 6 | 12 | 15 |
| Loss on debt extinguishment | -18 | - | - | - |
| Income before income taxes | 115 | 81 | 37 | 62 |
| Income tax expense | 26 | -21 | -5 | 44 |
| Net income | 89 | 103 | 42 | 18 |
| Foreign currency translation | - | - | - | 2 |
| Other comprehensive income (loss) | - | - | - | 2 |
| Total comprehensive income (loss) | - | - | - | 20 |
| Basic EPS | 0.71 | 0.786 | 0.34 | 0.15 |
| Diluted EPS | 0.69 | 0.75 | 0.33 | 0.14 |
| Basic Average Shares | 124,000,000 | 126,000,000 | 125,000,000 | 125,000,000 |
| Diluted Average Shares | 129,000,000 | 132,000,000 | 129,000,000 | 126,000,000 |
Indivior Pharmaceuticals, Inc. (INDV)
Indivior Pharmaceuticals, Inc. (INDV)